Merck & Co. Inc. Earnings Summary — Q1 2026

• Merck experienced a substantial net loss of $4.24 billion in Q1 2026, driven by an exceptional spike in Research & Development costs.
• R&D expenses soared to $12.59 billion in the latest quarter, compared to $3.89 billion in Q4 2025, likely indicating a large acquisition charge or milestone.
• Revenue growth remains resilient at 4.88% YoY, supported by market-leading positions in oncology (Keytruda) and vaccines (Gardasil).
• Operating income collapsed to negative $3.40 billion, a sharp reversal from the $3.85 billion profit recorded in the previous quarter.
• Gross profit margins remain healthy at approximately 74.2%, suggesting that core product manufacturing costs are stable.
• Shares outstanding decreased by 2.33% YoY, indicating continued execution of share repurchase programs to return capital despite earnings volatility.
• The company continues to face a 'bifurcated profile' with high revenue concentration in Keytruda as it approaches a 2028 patent cliff.

Management is focused on an aggressive deal-making culture to solve concentration risk and is transparent regarding the impact of the Inflation Reduction Act (IRA) and loss of exclusivity (LOE) timelines.

Deteriorating

The shift from a multi-billion dollar profit in late 2025 to a heavy loss in Q1 2026, driven by extreme R&D expense volatility, outweighs steady revenue growth.

Merck is in a transitional R&D phase, balancing massive commercial success with heavy investments in immunology and rare diseases to mitigate upcoming patent expirations.